Elinzanetant (BAY3427080) + Dabigatran etexilate
Phase 1Completed 0 watching 0 views this week๐ค Quiet
30
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Trial Timeline
Aug 5, 2022 โ Nov 14, 2022
NCT ID
NCT05471817About Elinzanetant (BAY3427080) + Dabigatran etexilate
Elinzanetant (BAY3427080) + Dabigatran etexilate is a phase 1 stage product being developed by Bayer for Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men. The current trial status is completed. This product is registered under clinical trial identifier NCT05471817. Target conditions include Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05471817 | Phase 1 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men